Menu Search
Equities

Oncodesign Precision Medicine Opm SA

ALOPM:PAR

Oncodesign Precision Medicine Opm SA

Actions
  • Price (EUR)1.01
  • Today's Change0.01 / 1.00%
  • Shares traded21.12k
  • 1 Year change-49.12%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 16:35 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in EURIncome statement in EURView more

Year on year Oncodesign Precision Medicine Opm SA's revenues fell -86.57% from 7.98m to 1.07m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 231.18k to a larger loss of 8.09m.
Gross margin130.48%
Net profit margin-754.61%
Operating margin-927.02%
Return on assets-46.23%
Return on equity-104.58%
Return on investment-63.87%
More ▼

Cash flow in EURView more

SmartText is unavailable
Cash flow per share-0.4711
Price/Cash flow per share--
Book value per share0.2219
Tangible book value per share0.1529
More ▼

Balance sheet in EURView more

Oncodesign Precision Medicine Opm SA has a Debt to Total Capital ratio of 70.52%, a higher figure than the previous year's 22.10%.
Current ratio2.53
Quick ratio--
Total debt/total equity2.39
Total debt/total capital0.7052
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.